Opinion|Videos|July 2, 2024
Going Beyond Topical Steroids and Calcineurin Inhibitors for AD Treatment
The panel examines the evolution of atopic dermatitis (AD) treatment beyond topical steroids and calcineurin inhibitors, while evaluating the safety and efficacy of a specific topical therapy in AD management.
Advertisement
Episodes in this series
- Based on your experience, how have topical treatments evolved beyond the use of topical steroids and topical calcineurin inhibitors?
- When it comes to topical ruxolitinib, how do you balance the efficacy versus the safety when deciding to treat patients with it?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
CLL Breakthrough: 100% Efficacy Reported for VenR Retreatment
2
AAP Breaks With CDC, Maintains Broader 2026 Childhood and Adolescent Vaccine Schedule
3
Trulicity, Botox Headline Drugs Included in the Third Cycle of Medicare Price Negotiations
4
New Dermatologic Therapies Make Waves at Maui Derm 2026
5
